โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 18 in last 7 days ๐ŸŽ Food: 180 in last 7 days ๐Ÿงธ Products: 48 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 18 in last 7 days ๐ŸŽ Food: 180 in last 7 days ๐Ÿงธ Products: 48 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago
๐Ÿ›ก๏ธ EUSW
๐Ÿ‡ฌ๐Ÿ‡ง
๐Ÿ’Š

Emtricitabine/Tenofovir disoproxil Mylan

emtricitabine;tenofovir disoproxil
HIV Infections
โœ… Authorised Generic
โœ…
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Treatment of HIV-1 infection: Emtricitabine/Tenofovir disoproxil Mylan is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1). Emtricitabine/Tenofovir disoproxil Mylan is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, (see sections 4.2, 4.4 and 5.1). Pre-exposure prophylaxis (PrEP): Emtricitabine/Tenofovir disoproxil Mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).

โš ๏ธ Patient safety

No

โš ๏ธ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.